GlassScriptPhysician profile
Natasha Chhabra
NPI 1013351675
$4,712.83
in general payments reported to CMS, 2019-2025
27 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $98.35 · 2021: $501 · 2022: $1,077 · 2023: $1,253 · 2024: $580 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250 · Education: $14.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.33 |
| Education | $14.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.06 | 2019-2025 | Linzess, Creon, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $669.68 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Celgene Corporation | $506.46 | 2021-2024 | Zeposia |
| Wilson Cook Medical Incorporated | $488.27 | 2019 | |
| Ardelyx, INC. | $344.58 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $280.09 | 2020-2025 | Talicia, Movantik, Aemcolo |
| Ironwood Pharmaceuticals, INC | $247.71 | 2021-2024 | Linzess |
| Pfizer INC. | $230.62 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.62 | 2020-2025 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $175.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $163.55 | 2021-2024 | Dificid |
| Janssen Biotech, INC. | $125.40 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Genzyme Corporation | $106.10 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $72.44 | 2019-2024 | Rebyota |
| Lilly USA, LLC | $53.27 | 2023-2025 | Omvoh |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $41.85 | 2021-2022 | |
| Braintree Laboratories, INC. | $36.54 | 2021-2023 | Sutab |
| Madrigal Pharmaceuticals | $35.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $31.12 | 2023-2025 | |
| Napo Pharmaceuticals INC | $30.18 | 2023 | Mytesi |
| Regeneron Healthcare Solutions, INC. | $18.05 | 2024 | Dupixent |
| Novo Nordisk INC | $17.71 | 2023 | Ozempic |
| Capsovision, INC. | $16.29 | 2023 | Capsocam Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2023 | Cyltezo |
| Celltrion USA INC. | $14.33 | 2024 | Zymfentra |
| Phathom Pharmaceuticals, INC. | $13.85 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Chhabra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.